- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
GTC’s Cooperative Model is designed to give laboratories, hospitals, and physician groups access to comprehensive genomic profiling through a more flexible and collaborative approach.
Whether the goal is to outsource testing to GTC or build in-house capabilities with GTC’s support, the model is built around shared expertise, advanced technology, standardized reporting, and improved access to high-quality molecular diagnostics.
GTC’s Cooperative Model is built to support different operational needs. Organizations can choose an Outsourcing Model, where testing and reporting are handled through GTC, or an Internalization Model, where GTC helps establish in-house wet lab capabilities while continuing to support validation, training, and reporting. This two-pathway structure gives institutions a practical way to access advanced genomic testing without a one-size-fits-all approach.
The co-op model allows laboratories and institutions to bring advanced genomic testing in-house without the need to build large bioinformatics, R&D, or assay development teams from scratch. By leveraging GTC’s established workflows, reporting infrastructure, molecular expertise, and ongoing support, partners can accelerate deployment, reduce operational complexity, and focus on delivering high-quality precision oncology testing to their patients.
The Co-Op Model is supported by GTC’s standardized reporting systems. These systems are AI-enabled and designed to include detailed findings, potential therapy recommendations, possible clinical trials, and other proprietary reporting elements. In the outsourcing model, reports can also be delivered with the co-op member’s logo, helping create a seamless experience for partner institutions while preserving consistency and quality in interpretation.
The cooperative approach is not limited to test access alone. In the internalization pathway, GTC supports cross-validation and training for technologists, while continuing to manage reporting remotely. This model is designed to help organizations expand testing capabilities, reduce turnaround time, and improve patient care by combining local operational capacity with GTC’s molecular expertise, informatics support, and established processes.
GTC’s comprehensive genomic profiling assays are designed for both domestic and global clinical adoption, with tests that are covered by Medicare, NY-state approved and carry both UKCA and CE Mark certifications. These recognitions reflect our commitment to delivering high-quality, clinically validated precision oncology testing while supporting broader patient access across the United States, United Kingdom, and Europe.
GTC’s Cooperative Model offers a more collaborative and standardized way to deliver comprehensive genomic profiling. By combining flexible implementation paths, standardized reporting, technical support, and shared expertise, it gives organizations a practical route to expand precision oncology capabilities while maintaining clinical quality and operational efficiency.
Explore our genomic tests, identify the right assay for your clinical scenario, and access the physician resources needed to support confident ordering and informed treatment decisions.
